Navigation Links
Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
Date:2/17/2011

SAN DIEGO, Feb. 17, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has been shown to reduce and/or block HCV infection in in vitro preclinical models and more recently, has displayed the potential to amplify the effectiveness of existing therapies in difficult to treat HCV-infected patients. This is in addition to CTS-1027's anti-inflammatory and anti-fibrotic effects which have been well established in models of acute hepatitis and liver fibrosis.

"Our previous clinical trials indicate that CTS-1027 used in combination with existing standard-of-care HCV drugs has the potential to impact the second phase of HCV virus inhibitory kinetics in patients. This phase is associated with the gradual reduction and replacement of HCV infected cells by new uninfected liver cells. While reducing HCV virus production in infected cells is extremely important, eliminating HCV-infected cells is crucial to curing HCV," said Dr. Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in combination with the existing standard-of-care drugs as well as the new antiviral drugs under development."

"We have established a collaborative relationship with key opinion leaders and clinical investigators in the hepatitis community," said Ms. MiRa Huyghe, Vice President of Clinical Development of Conatus. "We are encouraged by our investigators' interest in CTS-1027 and together with our investigators look forward to offering a new treatment option for HCV null responders."

"We are excited to participate in this Phase 2b trial of CTS-1027," said Dr. Paul J. Pockros, Head, Division of Gastroenterology/Hepatology at The Scripps Clinic and Director of the SC Liver Research Consortium in La Jolla, CA.  "Current treatment options for HCV null responders are very limited.  We believe CTS-1027 may enhance the effectiveness of pegylated interferon and ribavirin in this difficult to treat patient population."  

This clinical trial is a placebo-controlled, multicenter, double-blind, randomized trial of Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) with or without CTS-1027 in HCV null responders. Dosing will last for up to 48 weeks. The trial will also examine whether higher dose levels of CTS-1027 will improve on previously observed results.  The Company expects approximately 260 patients to be enrolled. The clinical trial will be conducted at up to fifty medical centers in the U.S.  Additional information about the trial can be found at: www.clinicaltrials.gov (Identifier NCT01051921) or http://www.clinicaltrials.gov/ct2/results?term=cts-1027.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027, is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.

Pegasys® and Copegus® are registered trademarks of F. Hoffman-La Roche, Inc.


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
2. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
3. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
4. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
7. Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration
8. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
9. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
10. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
11. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... June 19, 2017  Researchers from DRUGSCAN ® ... will host a live, complimentary webinar titled, "Untangling methods ... to the real world" on Wednesday June 28, 2017 ... This webinar will feature interviews with recreational and ... the manipulation techniques abusers use to prepare opioid tablets ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/9/2017)... AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), ... sale and distribution of the AeroForm® Tissue Expander System, ... commercial roll-out in the United States ... hundred (100) medical institutions and health systems, located throughout ... alternative for women who choose reconstructive surgery following a ...
Breaking Medicine Technology:
(Date:6/23/2017)... Va. (PRWEB) , ... June 23, 2017 , ... The ... the president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. ... Veterans Affairs. , Bowman brings an intimacy with the issues and challenges ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Everybody has ... it while others prefer to read it, and some people don't like it at ... pornography. Here's what they found: , Erotic literature can give readers a taste of ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products have reached ... the importance of correctly using a meat thermometer. The videos feature University of ... on consumer food safety habits. Dr. Bruhn explains the variety of meat thermometers ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... MD ... Florida. This is MD Now’s 28th facility overall and marks the urgent care center's ... located one mile North of The Falls shopping mall. The new clinic offers a ...
(Date:6/23/2017)... ... June 23, 2017 , ... American Farmer, will feature Chr. ... is slated to air fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on ... Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a groundbreaking discovery of ...
Breaking Medicine News(10 mins):